Friday, 16 Nov 2018

You are here

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia.  While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events.  A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.

Xie et al, performed a cohort analysis using  Medicare and MarketScan claims data on RA patients who initiated biologic therapies between 2006 and 2-15, looking for specific CV outcomes including myocardial infarction, stroke, and fatal CVD, 

From 88,463 RA patients they calculated the risk of CV events (crude incidence rate (IR) per 1000 patient‐years to range from 11.8 for etanercept to 17.3 for rituximab users. The crude incidence rate for pooled TNFi users was 15.0 (13.9‐16.3).

When compared to tocilizumab, the adjusted hazard ratios for CV events with biologics were:

  • Abatacept 1.01 (0. 79‐1.28)
  • Rituximab 1.16 (0.89‐1.53)
  • Etanercept 1.10 (0.80‐1.51)
  • Adalimumab 1.33 (0.99‐1.80)
  • Infliximab 1.61 (1.22‐2.12) for infliximab.

The data were similar using Marketscan data showing were no statistically significant differences in CVD risk between tocilizumab and any other biologics

Tocilizumab was associated with CVD risk comparable to etanercept, as well as a number of other RA biologics.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Should Immunoglobulins be Monitored with Rituximab Use?

Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.